Type of Mesothelioma:
Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation
Molecular Carcinogenesis 2022 December 23 [Link] Gautam Adhikary, Suruchi Shrestha, Warren Naselsky, John J Newland, Xi Chen, Wen Xu, Ashkan Emadi, Joseph S Friedberg, Richard L Eckert Abstract Glutamine addiction is an important phenotype displayed in some types of cancer. In these cells, glutamine depletion results in a marked reduction in the aggressive cancer phenotype.…
Read MoreBAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms
Oncogene 2022 December 22 [Link] Anita Singh, Sara Busacca, Aarti Gaba, Michael Sheaff, Charlotte Poile, Apostolos Nakas, Joanna Dzialo, Aleksandra Bzura, Alan G Dawson, Dean A Fennell, Andrew M Fry Abstract The tumour suppressor BRCA1-associated protein 1 (BAP1) is the most frequently mutated cancer gene in mesothelioma. Here we report novel functions for BAP1 in…
Read MoreIdentification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning
Frontiers in Endocrinology 2022 November 29 [Link] Yingqi Xiao, Wei Huang, Li Zhang, Hongwei Wang Abstract Background: Glycolysis-related genes as prognostic markers in malignant pleural mesothelioma (MPM) is still unclear. We hope to explore the relationship between glycolytic pathway genes and MPM prognosis by constructing prognostic risk models through bioinformatics and machine learning. Methods: The…
Read MoreNR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology
Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…
Read MoreDiverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8
Cell Immunology 2023 January [Link] Muneo Numasaki, Koyu Ito, Kiyoshi Takagi, Kengo Nagashima, Hirotsugu Notsuda, Hirokazu Ogino, Rika Ando, Yoshihisa Tomioka, Takashi Suzuki, Yoshinori Okada, Yasuhiko Nishioka, Michiaki Unno Abstract In this study, we sought to elucidate the roles of the interleukin (IL)-32β and IL-32γ in mesothelioma cell growth, and vascular endothelial growth factor (VEGF)-A…
Read MoreMultimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
Translational Lung Cancer Research 2022 November [Link] Laura V Klotz, Hans Hoffmann, Rajiv Shah, Florian Eichhorn, Christiane Gruenewald, Elena L Bulut, Raffaella Griffo, Thomas Muley, Petros Christopoulos, Philip Baum, Peter Huber, Seyer Safi, Marc Kriegsmann, Michael Thomas, Helge Bischoff, Hauke Winter, Martin E Eichhorn Abstract Background: The exact role and type of surgery for malignant…
Read MoreCDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
Cancers 2022 November 30 [Link] Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Roberta Alfieri, Graziana Digiacomo, Andrea Cavazzoni, Delia Cavallo, Massimo Corradi, Marcello Tiseo, Pier Giorgio Petronini, Mara Bonelli Abstract Background: The loss of the CDKN2A/ARF (cyclin-dependent kinase inhibitor 2A/alternative reading frame) gene is the most common alteration in malignant pleural…
Read MoreExtensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury
Annals of Surgical Oncology 2022 December 10 [Link] Lukas F Liesenfeld, Eva Quiring, Mohammed Al-Saeedi, Christian Nusshag, Markus W Büchler, Martin Schneider Abstract Background: Cisplatin (CDDP)-containing hyperthermic intraperitoneal chemotherapy (HIPEC) is frequently applied in selected patients with peritoneal malignancies derived from ovarian cancer, gastric cancer, and primary peritoneal mesothelioma. HIPEC with CDDP increases perioperative morbidity,…
Read MoreIdentification of a new potential plasmatic biomarker panel for the diagnosis of malignant pleural mesothelioma
La Medicina del Lavoro 2022 December 7 [Link] Luca Ferrari, Simona Iodice, Laura Cantone, Barbara Dallari, Laura Dioni, Lorenzo Bordini, Alessandro Palleschi, Carolina Mensi, Angela Cecilia Pesatori Abstract Background: Malignant pleural mesothelioma (MPM) is a rare highly aggressive tumor strongly associated with asbestos exposure and characterized by poor prognosis. Currently, diagnosis is based on invasive…
Read MoreThe STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model
Frontiers in Immunology 2022 November 18 [Link] Peter T Graham, Anna K Nowak, Scott M J Cornwall, Irma Larma, Delia J Nelson Abstract We assessed the murine Stimulator of Interferon Genes (STING) agonist, DMXAA, for anti-mesothelioma potential using the AE17-sOVA model that expresses ovalbumin (OVA) as a neo tumor antigen. Dose response experiments alongside testing…
Read More